Key Highlights

  • Third-quarter GAAP Earnings rose to USD 26.3 million, or USD 0.32 per diluted share, from USD 13.9 million, or USD 0.15, twelve months earlier.
  • Sales increased 8.9% to USD 341.3 million, with fertility services supplying USD 223.4 million and pharmacy services USD 117.9 million.
  • Adjusted EPS came in at USD 0.52, up from USD 0.45, and adjusted EBITDA advanced 6.3% to USD 58.4 million, equal to a 17.1% margin.
  • The 2026 guidance midpoint was raised, with Revenue now projected between USD 1.365 billion and USD 1.385 billion and adjusted EBITDA between USD 235.0 million and USD 240.0 million.

Gross Profit Growth Doubles Net Income

Progyny (NASDAQ:PGNY) reported third-quarter numbers on November 4, 2026. GAAP Net Income climbed to USD 26.3 million, or USD 0.32 per diluted share, from USD 13.9 million, or USD 0.15. The firm credited a larger Gross Profit base and smaller stock-based compensation charges, partly offset by reduced interest and other income. Gross profit grew 15% to USD 83.7 million, and gross Margin moved to 24.5% from 23.2%, a gain management linked to improved efficiency in care management services. Average members expanded to 7,176,000 from 6,757,000 a year earlier. Operating cash generation reached USD 56.6 million, versus USD 50.7 million previously.

A Record Selling Season and the Client Base Ahead for 2027

Progyny offers fertility and family building coverage to employers. The latest selling season brought a record 1.3 million newly covered lives and more than 85 new employer clients, while retention for 2027 sits near 100%. Leadership also reports interest in widening benefits to include pregnancy, parenting and menopause support. Fertility clients numbered 607 at September 30, 2026, compared with 553 a year earlier. Most incoming lives should activate in the first quarter of 2027, pushing client counts above 660 and covered lives to roughly 8.3 million. Utilization among all members registered 0.56% this quarter against 0.54%, while assisted reproductive cycles rose to 16,723 from 15,981. Client and covered-life counts both point to continued expansion heading into 2027.

Buybacks, Cash Balance and the Fourth-Quarter Projection

The company bought back close to 3 million shares for USD 82.7 million this quarter, leaving about USD 51 million of room under its May 2026 program. Cash and marketable securities of USD 195.6 million were USD 41.3 million lower than on June 30, 2026, and no borrowings exist against an undrawn USD 200 million revolver. For full-year 2026, net income is projected between USD 107.0 million and USD 110.6 million, which works out to between USD 1.30 and USD 1.35 a diluted share. For the fourth quarter, projected revenue spans USD 344.7 million to USD 364.7 million, while adjusted EBITDA is expected to land between USD 57.9 million and USD 62.9 million, which investors may weigh against the year's pace. The adjusted EBITDA margin declined from 17.5% because of planned platform spending, so earnings expansion hinges on gross margin improvement and steady engagement.

Where Things Stand

Net income almost doubled since gross profit outpaced costs, and a drop in Stock Compensation supported the GAAP line. Progyny (NASDAQ:PGNY) expanded revenue 8.9%, improved gross margin and nudged the guidance midpoint upward, though its adjusted EBITDA margin softened under platform outlays. Member activity remained solid as the fourth quarter began. Upcoming catalysts include fourth-quarter results, first-quarter 2027 client activations, additional repurchases and the company's 2027 outlook, slated for February alongside year-end results.